SuperworthBioCardia PE ratio BCDA
Share price divided by earnings per share over the last twelve months, since 2010.
- Today, Oct 23, 2026
- n/m
- not a meaningful number
- Last meaningful
- 75.0×
- Mar 2017
- Earnings per share, 12 months
- −$11.10
- to Dec 31, 2021
- Share price
- $0.92
- Oct 23, 2026
- Peer median
- 13.6×
BioCardia's PE ratio is not a meaningful number today: diluted EPS for one or more of the four quarters through 2026-06-30 is missing, so twelve months can't be added up.
It was last meaningful in Mar 2017, at 75.0×.
It has had no meaningful PE for most of its history, so the chart below shows the earnings per share a PE divides the price by.
Earnings per share over time
A PE divides the share price by these earnings. While they were a loss or a sliver, the PE meant nothing, so this chart shows the earnings themselves.
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2021 | −$11.10 | n/a |
| FY2020 | −$24.90 | n/a |
| FY2019 | −$41.70 | n/a |
| FY2018 | −$48.75 | n/a |
| FY2017 | −$44.55 | n/a |
| FY2015 | $0.00 | n/a |
| FY2014 | $0.00 | n/a |
| FY2013 | $0.00 | n/a |
| FY2012 | $0.00 | −100% |
| FY2011 | $162.00 | n/a |
| FY2010 | n/a | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q1 FY26 | −$0.21 | n/a | n/a | |
| Q2 FY25 | −$0.40 | n/a | n/a | |
| Q1 FY25 | −$0.59 | n/a | n/a | |
| Q4 FY21 | −$3.00 | n/a | −$11.10 | |
| Q3 FY21 | −$2.40 | n/a | −$11.55 | |
| Q2 FY21 | −$3.00 | n/a | −$13.65 | |
| Q1 FY21 | −$2.70 | n/a | −$17.55 | |
| Q4 FY20 | −$3.45 | n/a | −$24.90 | |
| Q3 FY20 | −$4.50 | n/a | −$29.25 | |
| Q2 FY20 | −$6.90 | n/a | −$34.20 | |
| Q1 FY20 | −$10.05 | n/a | −$38.85 | |
| Q4 FY19 | −$7.80 | n/a | −$41.70 |
Against its peers
Companies in Healthcare nearest BioCardia's size, closest first, today.
| Company | PE ratio |
|---|---|
| BCDABioCardia | n/m |
| NEPHNephros | 22.1× |
| ATNMActinium Pharmaceuticals | 4.2× |
| APTAlpha Pro Tech | 13.6× |
| SPROSpero Therapeutics | 10.1× |
| LFVNLifevantage | 14.7× |
| ICCCImmucell | 128× |
| KEQUKewaunee Scientific | 11.9× |
| Peer median | 13.6× |
What the PE ratio tells you
Share price divided by earnings per share over the last twelve months. It is the price tag on a dollar of profit: 20× means you pay $20 for $1 of yearly earnings.
Blank while earnings are negative. A very low PE can mean the market expects profits to fall, so read it with growth and the company's own history.
More on BioCardia
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.